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In the process of elucidating the progression of
events in intimal hyperplasia (IH), much attention
has been brought to stimulatory growth factors on
vascular smooth muscle cells (VSMCs). Increased
levels of cytokines, including PDGF,6,7 interleukin 1
(IL-1),8 tumor necrosis factor a (TNF- a ),9 and
bFGF,10 have been found in atherosclerotic plaques,
stenotic lesions, and arterial walls. Growth inhibitors
of VSMCs may also have an important role in vascu-
lar growth control. Gamma interferon ( g -IFN), a
product of activated T lymphocytes and natural
killer cells, inhibits VSMC proliferation in vitro.1-4
g -IFN infused into a rat carotid artery after balloon
catheter injury significantly decreased arterial steno-
sis.5 Inhibition of proliferation of VSMCs by 30% to
70% was seen when the gene for g -IFN was trans-
ferred and expressed in human endothelial cells and
then co-cultured with VSMCs.15 It was revealed by
means of immunolocalization and temporal distrib-
ution of several cytokines during the development of
vein graft IH that g -IFN was seen only in the con-
trol grafts.16
We have been studying the molecular events that
occur at the distal anastomosis after implantation of a
prosthetic arterial graft under in vivo flow condition
with a canine model of arterial grafting.11 By means of
the technique of messenger RNA (mRNA) differen-
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Purpose: By means of the technique of messenger RNA (mRNA) differential display, we
previously isolated a partial DNA clone found to be down-regulated at the polytetraflu-
oroethylene (PTFE) hyperplastic arterial anastomosis compared with the normal artery.
The partial DNA gene sequence was found to be homologous with interferon gamma
up-regulated protein (IGUP) first found in human psoriatic keratinocytes. We cloned
the entire IGUP gene from human vascular smooth muscle cells (VSMCs) to determine
its regulation by gamma interferon (g -IFN) and other cytokines in cultured human
VSMCs.
Methods: By means of polymerase chain reaction, the IGUP gene was amplified from a
QUICK-Clone complementary DNA human aorta kit using 5’ and 3’ oligonucleotide
primers to the known IGUP sequence. Immunohistocytochemistry studies compared
normal artery and distal anastomotic IH. Human VSMCs were stimulated with 1000
U/mL of g -IFN, 5 ng/mL of platelet-derived growth factor BB (PDGF-BB), 3.2
ng/mL basic fibroblast growth factor, 3.3 ng/mL transforming growth factor b (TGF-
b ), 10 ng/mL of vascular endothelial growth factor, and 10% fetal bovine serum (FBS)
for zero, 24, 48 and 72 hours. Western blot analysis of lysates of the stimulated VSMCs
was performed to determine up-regulation of IGUP. 
Results: DNA sequencing confirmed the cloning of the entire coding region of the IGUP
gene with 100% homology to the known IGUP DNA sequence. There was strong
expression of IGUP in quiescent VSMCs and marked reduction of expression of IGUP
in proliferating smooth muscle cells. g -IFN was the only cytokine, of the cytokines eval-
uated, to up-regulate production of IGUP in VSMCs. 
Conclusion: IGUP is a novel protein in VSMCs found to be down-regulated in areas of
anastomotic IH, as compared with a normal artery. We have now shown IGUP to be up-
regulated only by g -IFN in human VSMCs. IGUP may, therefore, be the intermediary
for the known g -IFN inhibition of human VSMC proliferation. (J Vasc Surg
1999;29:317-25.)
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tial display, we have been able to screen numerous
genes to gain insight into the molecular mechanism of
IH. Altered expression in several clones, including a
gene with homology to an interferon gamma up-reg-
ulated protein (IGUP), was revealed by means of
Northern blot analysis of 90-day distal anastomotic
segments of canine polytetrafluoroethylene (PTFE)
graft to aorta bypasses. Expression of the partial clone
representing IGUP was found to be decreased more
than threefold, to the level seen in a normal artery.12
IGUP was originally identified in a psoriatic, prolifer-
ative keratinocyte cell culture system.13 The up-regu-
lation of IGUP in keratinocytes was highly specific for
g -IFN, and its expression was not altered by other
cytokines, including bFGF, TGF- a , and IL-1. The
function of IGUP is unknown, but it shares some
characteristics with cytoskeletal proteins.14 The
deduced sequence of IGUP contains the tripeptide
ARG-GLY-ASP (RGD) sequence that is found in
many extracellular glycoprotein ligands of the integrin
family of receptors important for adhesion to matrix
molecules. We postulated that, as in keratinocytes, up-
regulation of IGUP is specific to g -IFN. We also
hypothesized that IGUP is expressed in normal arter-
ies, but has reduced expression in areas of IH.
The cloning and expression of the entire IGUP
gene from human VSMCs was studied. Strong IGUP
expression was shown in normal arteries by means of
immunocytochemistry studies, but marked reduction
of IGUP expression was shown in anastomotic IH.
We have also shown g -IFN specific up-regulation of
IGUP within human VSMCs. We therefore conclude
that IGUP may have an important role in the known
inhibition of growth by g -IFN stimulated VSMCs
and a role in the events of IH. 
MATERIALS AND METHODS
General materials. Human recombinant g -IFN,
platelet-derived growth factor BB (PDGF-BB), bFGF,
TGF- b , VEGF, trypsin-ethylenediamine tetraacetic
acid, penicillin/streptomycin/amphotericin B solu-
tion, sodium orthovanadate, aminoethylbenzenesul-
fonylfluoride, aprotinin, leupetin, Tris-HCL, NaCl,
Tween-20, and fetal bovine serum (FBS) were
obtained from Sigma Chemical (St. Louis, Mo). L-
glutamine, Dulbecco’s modified Eagle’s medium
(DMEM), ethidium bromide, and ultra pure agarose
were purchased from Gibco BRL Life Technologies
(Gaithersburg, Md). Polyacrylamide (0.2 m mol/L)
membrane, and b -mercaptoethanol were purchased
from BioRad Life Science Research Products
(Hercules, Calif). The EcoRI was purchased from
New England Biolab (Beverly, Md).
Cloning of the interferon gamma up-regulated
protein gene. A QUICK-Clone complementary
DNA (cDNA) human aorta kit was purchased from
Clontech (Palo Alto, Calif). Oligonucleotide
primers (TGCCCACTCCACTCCTTGTG and
GGTTGGGGAAAATCTGGAGTC) were con-
structed to the 5’ and 3’ ends of the known sequence
of IGUP. Oligos Etc. (Wilsonville, Ore) constructed
the oligonucleotide primers. Standard polymerase
chain reaction (PCR) technique (Maniatis, Molecular
Cloning) was then used to amplify cDNA clones with
the IGUP specific primers. 
Sequencing of the interferon gamma up-reg-
ulated protein gene. The cDNA clones were then
subcloned with the TA Cloning Kit (Invitrogen
PCR 2.1, Carlsbad, Calif). Ligation products were
transformed into competent Escherichia coli and
plated for kanamycin resistance. White colonies were
selected, and alkaline lysis miniprep was performed
to isolate the plasmids. The presence of an insert was
confirmed by means of ethidium bromide staining
after restriction enzyme digestion with EcoRI and
1% agarose gel electrophoresis. The cDNA clones
were sent to Dana Farber Cancer Institute Core
Facility (Boston, Mass) for DNA sequencing.
Cell culture. VSMCs were purchased from NIA
Aging Cell Culture Repository, Coriell Institute for
Medical Research (Camden, NJ; Repository No.
AG11545A). VSMCs were grown in a humidified
incubator with 5% CO2/95% air at 37°C in DMEM
supplemented with 10% FBS. Cells were fed twice
weekly and passaged by means of trypsinization at
confluence. Third to fourth passage cells were grown
to confluence in 100 mm plates for cell protein analy-
sis and then serum-starved for 48 hours. Cells were
trypsinized and replated at 300,000 VSMCs per 100
mm plate and then stimulated with 1000 U/mL of
g -IFN, 5 ng/mL of PDGF-BB, 3.2 ng/mL of bFGF,
3.3 ng/mL of TGF-b , 10 ng/mL of VEGF, and 10%
FBS for zero, 24, 48, 72 hours. After each stimula-
tion period, the cells were washed with ice-cold phos-
phate buffer (PBS) and lysed with the addition of ice-
cold lysis buffer (200 m mol/L sodium orthovana-
date, 1 m g/mL each of aprotinin and leupeptin, and
1 m M4-[2-aminoethyl] benzenesulfonylflouride-
HCL) for 15 minutes, on ice with gentle shaking.
Lysates were clarified by means of centrifugation for
10 minutes at 14,000 rpm, and the supernatant was
collected. Boiled samples were separated by means of
10% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to PVDF
(0.2 m mol/L) membrane. Western blots were
blocked and incubated with primary antibody, as
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described. The blots were incubated for one hour
with biotinylated horseradish peroxidase streptavidin
complex secondary antibody (anti-rabbit). The blots
were again washed with tris-buffered saline–TWEEN
and imaged by means of the chemiluminescence
(ECL) detection method (Amersham, Arlington
Heights, Ill). The results of the signals were detected
on X-AR film (Fischer, Springfield, NJ).
Immunohistochemistry. Four micron sections
were deparaffinized and rehydrated. Sections were
coated with serum-free protein block (DAKO) for
15 minutes, followed by three PBS washes. Anti-
IGUP antibody was applied to sections in a 1 to 100
dilution and incubated overnight at 4°C. Three PBS
washes were used to remove the primary antibody,
and secondary antibody (universal IgG, DAKO) was
applied for 30 minutes. Detection was by means of
streptavidin peroxidase incubation for 30 minutes,
followed by development with 3’amino 9’ethyl car-
bazole. Sections were counterstained with hema-
toxylin.
RESULTS
Cloning and expression of the interferon
gamma up-regulated protein gene. By means of
the known DNA sequence of IGUP cloned from ker-
atinocytes, two oligonucleotide primers were con-
structed to the 5’ and 3’ ends of the IGUP DNA
sequence. The two primers (TGCCCACTCCACTC-
CTTGTG and GGTTGGGGAAAATCTGGAGTC)
were constructed so that the entire coding sequence
of the IGUP gene and select single restriction sites
that aided in the subsequent subcloning would be
transcribed. The QUICK-Clone aorta cDNA kit was
used in place of the time-consuming process of library
screening. Three human QUICK-clone aorta cDNAs
with the IGUP-specific primers were amplified. The
amplification products were noted to be approximate-
ly 1000 base pair (bp). The known DNA sequence of
IGUP from keratinocytes is 985 bp. 
Cloning and sequencing of the interferon
gamma up-regulated protein gene. The IGUP
cDNA clones were subcloned into the PCR 2.1 vec-
tor by means of the TA Cloning Kit (Invitrogen) to
aid in DNA sequencing. The DNA samples isolated
by means of the alkaline miniprep were then restric-
tion enzyme digested with EcoRI to determine the
presence of the insert within the vector. Those three
clones were sent to the Dana Farber Cancer Institute
Core Facility for DNA sequencing. Fig 1 shows the
full sequence of IGUP (cDNA clone 1) cloned from
human aorta cDNA. The human vascular IGUP
gene is noted to have the complete coding sequence
and also 100% homology to the IGUP gene isolated
from keratinocytes. The deduced amino acid
sequence of IGUP shows that the protein contains
the RGD sequence found in many extracellular gly-
coprotein ligands of the integrin family of receptors.
Gamma interferon up-regulation of interferon
gamma up-regulated protein in vascular smooth
muscle cells. IGUP was first identified in a prolifera-
tive keratinocyte cell culture system. Its stimulation
was highly specific for g -IFN, and its expression was
not altered by other cytokines. The presence of IGUP
and the effect of vascular cell cytokines on the expres-
sion of IGUP in human VSMCs had never been deter-
mined. We studied the effect of g -IFN, PDGF-BB,
bFGF, TGF-b , VEGF, and BSA on IGUP protein lev-
els in a human VSMC culture system. The VSMCs
were stimulated with the different cytokines for zero,
24, 48, and 72 hours. Expression of IGUP protein was
analyzed by means of Western blot analysis with anti-
IGUP antibody. Fig 2 shows that although IGUP was
constitutively expressed in VSMCs, the only tested
cytokine that up-regulated IGUP was g -IFN.
Immunohistochemistry. Fig 3 shows a canine
abdominal aorta 90 days after carotid-aortic recon-
struction with an ePTFE graft. This section, taken
from the area near the distal anastomosis, was
stained with anti-IGUP antibody to reveal protein
expression of IGUP in the section. The area of IH
shows virtually no staining for IGUP, whereas the
area of nonproliferating VSMCs (internal control)
shows marked positive staining.
DISCUSSION
Anastomotic IH in prosthetic arterial grafts
remains a major cause of delayed graft failure.17-19 IH
occurs after all forms of vascular injury, including bal-
loon catheter denudation, endarterectomy, or place-
ment of a vascular graft. The characteristic progres-
sion of the hyperplastic lesion involves migration and
proliferation of VSMCs from the media into the inti-
mal layer. The release of locally derived growth factors
is believed to initiate VSMC proliferation and migra-
tion, thus propagating the stenosis of native vessels
and vascular grafts.20,21 VSMCs in a quiescent state in
normal arteries undergo phenotypic, proliferative, and
migratory changes, probably induced by certain genes
being turned on, off, or a combination of both.
We were successful in cloning the entire gene for
IGUP from human VSMCs, and we found the
sequence to be 100% homologous to the human ker-
atinocyte IGUP I-5111 gene. As yet, there is no
known function of IGUP. We can, however, draw
some conclusion of its function from the DNA and
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amino acid sequence. IGUP does share some charac-
teristics with cytoskeletal proteins, or proteins that are
associated with the cytoskeleton. In addition, IGUP
contains the tripeptide RGD, which is characteristic of
extracellular glycoprotein ligands of the integrin fami-
ly of receptors. Several members of the integrin family
of receptors recognize and bind the RGD sequence
that is thought to play a key role in cell adhesion.22
IGUP may therefore be an intermediary in the control
of VSMC adhesion and migration.
We also showed in this study that IGUP was up-
regulated, as in the keratinocytes, specifically by
means of g -IFN. g -IFN not only has antiviral proper-
ties, but it also can retard proliferation of many cell
types, including VSMCs.1-5 When a gene for g -IFN
was transferred into balloon-injured arteries, it
reduced VSMC proliferation and intimal formation.23
When the gene for g -IFN was transferred into
endothelial cells co-cultured with VSMCs, there was a
30% to 70% decrease in proliferation of VSMCs com-
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Fig 1. Nucleotide sequence of cDNA 1 encoding interferon gamma up-regulated protein
(IGUP). The cDNA is of 985 bases and has 100% homology to the known sequence of IGUP
in keratinocytes. The RGD sequence is at position 181 to 183 (underlined).
pared with control cells.15 As g -IFN up-regulates
IGUP protein production, IGUP may be an interme-
diary through which g -IFN inhibits proliferation of
VSMCs. 
Immunohistocytochemistry studies revealed
strong IGUP expression in quiescent smooth muscle
cells. There was a marked reduction of IGUP
expression in hyperplastic, proliferative smooth mus-
cle cells. Our data showed that IGUP protein is
located in the intima and media of normal arteries
and veins of canine, human, and rat blood vessels.
Thus, this protein appears to be preserved in vascu-
lar cells across species and is lost after proliferation in
vascular injury models and after arterial bypass in
humans. This data further supports the hypothesis
that IGUP may be involved in maintaining VSMCs
in a nonproliferative state.
For this hypothesis to work, g -IFN needs to be
secreted by circulating or adjacent cells, thus stimulat-
ing VSMCs to produce IGUP. Immunolocalization
and temporal distribution of several cytokines during
the development of vein graft IH has recently been
described.16 In an experimental rat model, maximal
hyperplasia occurred 2 weeks after the grafting proce-
dure. The cytokines IL-1b and bFGF were released
earliest, at 2 days. PDGF-AA and TNF-a then prop-
agated the process with their release at 2 weeks and 1
week, respectively. Therefore, the early release of 
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Fig 2. A, Western blot analysis of human vascular smooth muscle cells stimulated with gamma
interferon (1000 U/mL) and platelet-derived growth factor BB (PDGF-BB; 5 ng/mL). Note
up-regulation of interferon gamma up-regulated protein (IGUP) in human vascular smooth
muscle cells that were stimulated with gamma interferon. Up-regulation began to occur at
approximately 48 hours after stimulation (Arrow, IGUP approximately 30 kd). Molecular
weight standards are given in kilodaltons for all blots. B, Western blot analysis of human vas-
cular smooth muscle cells stimulated with bFGF (3.2 ng/mL) and transforming growth factor
b (3.3 ng/mL). No up-regulation of protein predicted at 28.7 kd was seen during the stimu-
lation period (arrow). C, Western blot analysis of human vascular smooth muscle cells stimu-
lated with VEGF (10 ng/mL) and 10% fetal bovine serum. IGUP noted to be constitutively
produced by vascular smooth muscle cells, but no up-regulation of IGUP was noted during
the stimulation period (arrow).
IL-1b and bFGF and the down-regulation of g -IFN
triggered an inflammatory response, initiating IH.
A sequence of events that occurs during response
to vascular injury can therefore be elucidated from
these studies. From the studies determining immuno-
localization and temporal distribution of cytokine
expression, vascular response to injury is controlled by
means of growth promoting and inhibiting factors. In
the quiescent state (control artery), g -IFN was the
cytokine present. Two days after vascular injury, IL-
1b and bFGF were expressed. Both IL-1b and bFGF
have been shown to potentiate the activity of PDGF.
IL-1b indirectly stimulates VSMC proliferation8 by
inducing expression of both PDGF and PDGF-BB
receptors on VSMCs.24 bFGF has been shown to pro-
mote VSMC migration and potentiate chemotaxis to
PDGF-BB.25 PDGF released from platelets and
monocytes on the vascular surface drives the migra-
tion of VSMCs from the media to the intima.26
PDGF-AA expression paralleled the development of
IH, peaking at 2 weeks and then declining. TNF-a
expression increased at 1 week and remained elevated.
TNF- a has been shown to substantially enhance 
g -IFN induced expression of Ia antigens.27 g -IFN not
only is an efficient inhibitor of VSMC proliferation,
by means of blocking their progression in the G1
phase of the cell cycle, but also enhancing expression
of Ia antigen. VSMCs expressing the Ia antigen were
found to be nonproliferative.3
The process of change from a quiescent to a pro-
liferating VSMC is a complex event resulting from
numerous cellular events, including leukocyte infil-
tration and activation. With injury, this balance is
strongly shifted toward VSMC proliferation, proba-
bly overwhelming the inhibitory effects of g -IFN. 
Our present results have described a novel pro-
tein, IGUP, found in normal arteries, but down-reg-
ulated in areas of vascular injury. This protein con-
tains the RGD sequence known to be important in
cell adhesion. We have also shown that, as in ker-
atinocytes, g -IFN was the only cytokine to up-regu-
late protein production in human VSMCs. Knowing
the g -IFN is an inhibitor of VSMC proliferation, we
propose that IGUP may have a role in inhibition of
VSMC growth and possibly be important in main-
taining adhesion of human VSMCs.
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Fig 3. Immunohistochemical staining using anti-interferon gamma up-regulated protein
(IGUP) antibody of a canine abdominal aorta 90 days after carotid-aortic reconstruction with
an ePTFE graft. This section, taken close to the distal anastomosis shows positive staining of the
aortic smooth muscle cells (brown staining) and virtually no staining of the intimal hyperplastic
smooth muscle cells (IH). The arrows delineate the most superior lamella on the aortic wall.
To confirm our conclusions, we plan further cell-
culture studies to help elucidate the importance of
IGUP in the regulation of proliferation of VSMCs. If
IGUP is important in the regulation of proliferation
of VSMCs, then its overexpression by adding the
protein to the supernatant of cultured cells or its
overexpression by transfection experiments should
show decreased proliferation of VSMCs. Also, if
IGUP is important in adhesion and migration of
VSMCs, then overexpression of the protein will allow
for greater adhesion and less migration of VSMCs. In
contrast, by blocking the IGUP protein with anti-
body, VSMCs should adhere less and migrate more. 
In conclusion, we have identified a unique pro-
tein in VSMCs, IGUP. IGUP may play a role in the
regulation of proliferation, adhesion, and migration
of VSMCs. We plan further cell-culture and adhe-
sion and migration studies to help elucidate the
function of IGUP and further elucidate the progres-
sion of events in IH.
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Dr Bauer E. Sumpio (New Haven, Conn). I would
like to congratulate the authors on this study, which obvi-
ously represents many long hours of laboratory work. 
Intimal hyperplasia is a well-recognized and common
complication of distal bypass grafting. Although the tem-
poral and morphological features of this entity have been
well described, the underlying molecular events remain
elusive. Differential display was first described in 1992 and
is a creative technique that allows for the quick and sensi-
tive screening of a large number of genes from small
amounts of tissue. 
Dr LoGerfo and his colleagues have used this tech-
nique of differential display to identify differences in gene
expression between anastomotic intimal hyperplastic tissue
and normal tissue. Four years ago at our Vascular Society
meetings in Seattle, his group first reported and subse-
quently published on the isolation of up to 11 genes that
were differentially expressed at the downstream anasto-
mosis of the canine model by means of this technique of
differential display. At that time, they focused their atten-
tion on a clone, the expression of which was decreased
threefold in tissue from intimal hyperplastic lesions.
Isolation of the clone, as stated today, showed the DNA
sequence homology to the gamma interferon-induced
gene or IGUP. 
This study is a logical extension of their previous work.
Dr Rzucidlo and her co-workers have now successfully
cloned the IGUP gene from human vascular smooth mus-
cle cells and have shown that only gamma interferon, and
not PDGF, bFGF, TGF-beta, or VEGF, can up-regulate the
expression of IGUP in human vascular smooth muscle cells. 
I have a number of questions concerning the conclu-
sions and the interpretation of data. 
First, I’d like to emphasize that the demonstration of
IGUP up-regulation by gamma interferon is in cultured
smooth muscle cells. More compelling evidence would be
demonstrating the expression of the IGUP gene and
showing that it’s also similarly regulated. Did the authors
perform Northern analysis to determine if the gamma
interferon would increase IGUP transcription in these cul-
tured smooth muscle cells? 
Second, I take issue with the conclusion in the manu-
script that “IGUP may, therefore, be the intermediary for
the known gamma interferon inhibition of human smooth
muscle cell proliferation.” It has not been shown that
gamma interferon is down-regulated in areas of anastomot-
ic intimal hyperplasia, as compared with the normal artery.
It is also unknown whether a decrease in gamma interferon
is causally linked to a decrease in IGUP, basically the con-
verse of this study. Also, it is not established that IGUP plays
any antiproliferative role, or any role for that matter, in
smooth muscle cells. So, have the authors measured by
means of a Northern blot using their IGUP cDNA for
changes in gene expression in their anastomotic lesions?
Can they prove that the expression of IGUP is decreased?
And will they show that overexpression of IGUP or pre-
venting its decrease would diminish smooth muscle cell pro-
liferation? I believe this is the crux of the issue. 
My last question regards the protein that they have
cloned, IGUP. Could they tap into the knowledge that
they’ve gleaned from the sequence data of the IGUP clone
because it shares some characteristics of the skeletal pro-
teins? Also, as Dr Rzucidlo has pointed out, there is an
RGD sequence within this which makes it very interesting
in its relationship with the integrins. Have they performed
any immunohistochemical staining with their antibodies to
IGUP to determine its distribution in smooth muscle cells? 
I would like to thank the authors again for their fine
work.
Dr Eva M. Rzucidlo. Thank you, Dr Sumpio, for your
thoughtful comments and questions. 
We are planning to do cell culture work in which the
present experiment would be repeated using messenger
RNA Northern blot analysis. We are also starting a study to
determine other triggers for IGUP up-regulation. We are
creating arterial venous fistulas in the canine model to deter-
mine the effect of increased flow and IGUP expression.
We certainly have not proven that IGUP has an
antiproliferative effect. We know that gamma interferon
decreases proliferation of vascular smooth muscle cells. We
know that gamma interferon increases expression of IGUP
in vascular smooth muscle cells. We have shown in unpub-
lished data that anti-IGUP antibody can block the
antiproliferative effect of gamma interferon. We also have
found that this effect is specific to gamma interferon and
not to other cytokines.
In our study, we did not show that gamma interferon
is down-regulated in areas of anastomotic intimal hyper-
plasia. However, there is a paper from a group in
Montefiore, NY, that has shown that gamma interferon is
only found in normal arteries.
We also thought that it was very interesting that IGUP
has the RGD sequence. IGUP may play a role in decreas-
ing proliferation of vascular smooth muscle cells, but I
think it has a more important role in the migration of
smooth muscle cells. We have performed some migration
studies that have shown that by adding IGUP antibody we
reversed the increased migratory effect of gamma interfer-
on on vascular smooth muscle cells. 
As far as the immunohistochemistry studies, I think the
one slide of the composite graft of our anastomosis does
show that in the area of intimal hyperplasia there is decreased
expression of IGUP. In the composite picture, you can also
identify decreased expression of IGUP in the area of dam-
aged smooth muscle cells (where the vascular clamp was).
We have not done any studies showing where in the smooth
muscle cells IGUP is located. We suspect it is within the
membrane from the predicted amino acid sequence.
Dr Alexander W. Clowes (Seattle, Wash). I would just
like to make a comment. I think this is a terrific piece of work
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and very well done, but I want to warn you against being
biased by the name that’s first applied to the protein. I would
point out that platelet-derived growth factor is neither
platelet specific nor growth factor specific, and it has many
other functions. And I would suggest, based on your
immunohistochemistry of normal vessels, that this may have
nothing to do with gamma interferon and its most impor-
tant functions may be other. Because there aren’t any T cells
in the normal vessel, and therefore there is no gamma inter-
feron, how did you get staining of a normal vessel? Perhaps
you can think about that or give us some thoughts now. But
in the future, as you expand this work, don’t get hung up on
the idea that it’s gamma interferon that induces this protein. 
Dr Rzucidlo. Thank you, Dr Clowes. There is one study
that I found quite intriguing done by the group in
Montefiore, NY. The study involved interposing a rat epi-
gastric vein in the femoral artery. Temporary distribution of
different cytokines were measured. Within two hours, at
which point intimal hyperplasia began according to this
group, gamma interferon disappeared. The question is, from
where is gamma interferon coming? Peter Libby from
Boston has shown that vascular smooth muscle cells can
make beta interferon. The beta interferon could be stimulat-
ing the cells at rest. When the cells are damaged, other
cytokines overpower the effect of interferon, causing the
resultant intimal hyperplasia.
Dr John A. Mannick (Boston, Mass). I think this is a
wonderful example of the application of cutting-edge
techniques of molecular biology to a problem that is of
interest to every clinician in the room, and I congratulate
you on a great piece of work. 
Dr Clowes asked my first question about where you
think the gamma interferon might be coming from in the
arteries. There doesn’t seem to be a whole lot of T cells or
NK cells. 
The second question I had was about relating your
findings to another phenomenon that’s described by Peter
Libby’s laboratory, namely, the increased production of
gamma interferon in unstable plaque. Can we relate the
effects of gamma interferon in down-regulating IGUP to
the observation that with high levels of gamma interferon
there is defective repair of the fibrous cap on a plaque?
Dr Rzucidlo. Thank you, Dr Mannick. In the athero-
sclerotic plaques, there are a lot of T lymphocytes that
produce gamma interferon. Other groups have shown that
gamma-interferon–stimulated cells increase the number of
MHCII receptors. Vascular smooth muscle cells express-
ing MHCII receptors do not proliferate and have more
apoptosis. The vascular smooth muscle cells are therefore
not only not proliferating, but also decreasing in number
because of apoptosis. This may lead to increased plaque
instability and rupture.
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